IN2 COST-EFFECTIVENESS (CE) OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)  by Grima, DT et al.
446 Abstracts
converted into an estimate of the number of HIV infec-
tions averted by the intervention. For each averted 
infection replicate, the corresponding savings in future
HIV-related medical care costs and quality-adjusted life
years (QALYs) were estimated. This sampling process was
repeated 5000 times to yield a distribution of the INHB
describing the full post-data uncertainty. RESULTS: We
obtained a positive mean INHB, 0.0008 (close to zero),
indicating that advocacy training is just slightly favored
over the comparison condition for men, assuming a
$50,000 per QALY threshold. We also displayed the
acceptability curve: to be somewhat conﬁdent of the cost-
effectiveness of advocacy training over the comparison
condition, say at 0.7 probability, one should be willing to
spend over $100,000 per QALY. CONCLUSIONS: The
Bayesian framework provides a powerful tool to the econ-
omist who intends to advise policy makers by allowing
the question—whether an intervention is cost-effective—
to be addressed directly.
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OBJECTIVE: To examine the CE of adding minipool
NAT to current blood screening (CS) of volunteer blood
donations to reduce the risk of HBV, HCV and HIV infec-
tion in the United States. METHODS: We developed 
a decision analytic model of screening volunteer blood
donations in the US based on recently published Markov
models of HBV, HCV, and HIV infection to estimate 
discounted lifetime costs and quality-adjusted life year
(QALY) gains. Infection risk (including prevalence and
the window period between antigen and antibody
detectability in the donated blood), and test sensitivities
were derived from the literature. Age-speciﬁc 10-year sur-
vival of transfusion recipients was from Vamvakas (1994)
and the age distribution from a private managed care
database for transfusions in 1995. Secondary analyses
considered alternative screening strategies. RESULTS:
The model estimated NAT would annually prevent 37,
128 and 7 transfusion-acquired cases of HBV, HCV, and
HIV respectively compared to CS alone (6.2 million trans-
fusion recipients). HCV had the greatest impact on total
QALYs and costs. Although the cost per case of HIV
avoided was 3–4 times that for HBV or HCV, the overall
impact of HIV on CE was small. Adding NAT to CS
would add 86 life years, at an incremental cost per life
year gained of $2.1M and an incremental cost per QALY
gained of $1.2M. The CS + NAT-p24 strategy dominated
CS + NAT, and had an incremental cost per QALY of $0.9
M compared to CS. Results were most sensitive to disease
incidence rates, screening test costs, estimates of window
period closure, and the age distribution of transfusion
recipients. CONCLUSIONS: The CE of adding NAT to
current screening, although not within a range considered
cost-effective for health care treatments, may be reason-
able when considered in the context of other blood-
related preventive interventions such as autologous blood
donation, and the desire for a zero tolerance level for
infections from blood transfusions.
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OBJECTIVES: The use of antiretroviral therapy has enor-
mous success in slowing down disease progression in
HIV/AIDS. Combinations of therapeutics have resulted in
declining rates for opportunistic infections and mortality.
The high costs of these medications have prompted ques-
tions about their cost-effectiveness. Most studies esti-
mating cost-effectiveness of combination antiretroviral
therapy (HAART) use data from a short period of time.
Data is often collected during six months. In this study,
the impact of using an extended study period of two years
to assess the long-term effects of HAART is investigated.
METHODS: To estimate the impact of a longer period of
data collecting, data from the HIV-database from the 
University Hospital of Groningen were used. This data-
base contains data on among others hospital admission
data, opportunistic infections and serologic markers of
over 300 patients since 1996. A Markov transition model
for disease progression was developed. Using data from 
a 2-year period, the Markov transition probabilities and
the ﬁnal Markov reward was calculated. This was com-
pared with an analysis in which data from a 6-month
period were used. RESULTS: When compared with pro-
gression rates based on 6-month data, smaller progres-
sion rates were found when the model was based on a
2-year data. The use of a 2-year data period for Markov
modelling was associated with better health outcomes 
than with a model based on 6-month data. Since the 
modelling of outcomes is closely associated with costs, 
a decline in costs was also seen. Overall, the cost-
effectiveness of HAART was more favourable when the
model was based on data from a 2-year period. CON-
CLUSIONS: The use of an extended study period for mod-
elling the long-term effect of HAART leads to signiﬁcantly
different results. It is likely that the use of a relatively 
